OQROGet OQRO Pro
Insider trade

Tenax Therapeutics (TENX)CEO bought ~$3.4K

Christopher Thomas Giordano, CEO at Tenax Therapeutics, bought ~$3.4K of Tenax Therapeutics shares.

~$3.4K
Approx. value · 455 sh @ $7.51
2,067
Holds after · shares reported
Traded
Nov 19, 2025
Filed
Nov 20, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Nov 12, 2025Company filing · Form 8-K · ResultsReported its results
  2. Nov 17, 2025Insider · 2 peopleInsiders: 4 purchases (~$59K)
  3. Nov 18, 2025Insider · 2 peopleInsiders: 2 purchases (~$27K)
  4. Nov 19, 2025 · this disclosureInsider · 3 insiders in a week, a first since 2010CEO purchased ~$3.4K of TENX shares in the open market

What came next

  1. Nov 20, 2025Insider · 3 insiders in a week, a first since 2010CEO purchased ~$4.1K of TENX shares in the open market
  2. Dec 2, 2025Insider · Their first buy on recordDirector purchased ~$9K of TENX shares in the open market
  3. Dec 3, 2025InsiderDirector purchased ~$14K of TENX shares in the open market
  4. Dec 4, 2025InsiderDirector purchased ~$23K of TENX shares in the open market
  5. Dec 8, 2025InsiderDirector purchased ~$25K of TENX shares in the open market
  6. Dec 9, 2025InsiderDirector purchased ~$26K of TENX shares in the open market
  7. Jan 6, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On January 6, 2026, the Company and its Chief Medical Officer, Dr. Stuart Rich, entered into a second amendment to Dr. Rich’s Executive Employment Agreement dated January 15, 2021, as amended on June 12, 2024 (the “Employment Agreement Amendment”).”
  8. Mar 10, 2026Company filing · Form 8-K · ResultsReported its results
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Tenax Therapeutics

For Tenax Therapeutics, OQRO holds 11 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its TENX page.

Other recent filings by Christopher Thomas Giordano, CEO

The full history of Christopher Thomas Giordano, CEO is on the profile page.

How this filing works

Other disclosures at Tenax Therapeutics

Everything OQRO holds on this company is on its TENX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data